The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Revised Response Criteria for Malignant Lymphoma
Open accessAbstract
Purpose: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Methods: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18 F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. Results: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. Conclusion: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationWotherspoon, A. C., Diss, T. C., Pan, L., Isaacson, P. G., Doglioni, C., Moschini, A., & de Boni, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)91409-f · Cited by 2,118
Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,335
Self-citationAbrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 914
Self-citationPositron-Emission Tomography and Assessment of Cancer Therapy
Juweid, M. E., & Cheson, B. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050276 · Cited by 750
Self-citationHutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 726
Self-citationJerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999) · Blood · doi:10.1182/blood.v94.2.429 · Cited by 565
Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J.-D., Belhadj, K., Gaulard, P., Garderet, L., Lepage, E., Reyes, F., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0272 · Cited by 494
Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.414 · Cited by 465
Self-citationUtility of FDG-PET scanning in lymphoma by WHO classification
Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J.-A., Zhuang, H., Pitsilos, S., Bagg, A., Downs, L., Mehrotra, A., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2778 · Cited by 437
Cited by
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Self-citationHallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationFrom RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
“Progression in the lungs, particularly in the presence of potential inflammation or infection while a patient is on treatment, should be viewed with great caution, as discussed in the revised response criteria in lymphoma (32,33).”
BackgroundMethodInfluentialPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citationBarrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116133 · Cited by 1,607
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Self-citationKochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationPI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Self-citationSavoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Self-citationChen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1316 · Cited by 989
Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., Walewski, J., André, M., Johnson, P. W., Pfreundschuh, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv304 · Cited by 930
Younes, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J. M., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30167-x · Cited by 927
Standards for PET Image Acquisition and Quantitative Data Analysis
Boellaard, R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057182 · Cited by 902
Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6525 · Cited by 846
Self-citationObinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 800
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708984 · Cited by 789
Self-citationSenter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0793 · Cited by 759
Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., Pro, B., Pileri, S., Pulsoni, A., Soubeyran, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3991 · Cited by 751
Self-citationDavids, M. S., Roberts, A. W., Seymour, J. F., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S., Kipps, T. J., Anderson, M. A., Salem, A. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4320 · Cited by 748
Friedberg, J. W., Sharman, J., Sweetenham, J., Johnston, P. B., Vose, J. M., LaCasce, A., Schaefer-Cutillo, J., De Vos, S., Sinha, R., Leonard, J. P., et al. (2010) · Blood · doi:10.1182/blood-2009-08-236471 · Cited by 747
Self-citationMoskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60165-9 · Cited by 742
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Self-citationHorwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32984-2 · Cited by 739
Self-citationGreen, T. M., Young, K. H., Visco, C., Xu-Monette, Z. Y., Orazi, A., Go, R. S., Nielsen, O., Gadeberg, O. V., Mourits-Andersen, T., Frederiksen, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4342 · Cited by 686
Armand, P., Shipp, M. A., Ribrag, V., Michot, J.-M., Zinzani, P. L., Kuruvilla, J., Snyder, E. S., Ricart, A. D., Balakumaran, A., Rose, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3467 · Cited by 670
Olsen, E. A., Whittaker, S., Kim, Y. H., Duvic, M., Prince, H. M., Lessin, S. R., Wood, G. S., Willemze, R., Demierre, M.-F., Pimpinelli, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0630 · Cited by 666
Self-citationWhittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664
Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 663
Fajgenbaum, D. C., Uldrick, T. S., Bagg, A., Frank, D., Wu, D., Srkalovic, G., Simpson, D., Liu, A. Y., Menke, D., Chandrakasan, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-746933 · Cited by 648
Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., MacDonald, D., Hertzberg, M., Kwan, Y.-L., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 643
Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60605-9 · Cited by 641
Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Král, Z., Fuchs, M., Hallek, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61940-5 · Cited by 635
Self-citationItaliano, A., Soria, J.-C., Toulmonde, M., Michot, J.-M., Lucchesi, C., Varga, A., Coindre, J.-M., Blakemore, S. J., Clawson, A., Suttle, B., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30145-1 · Cited by 627
Scott, D. W., Wright, G. W., Williams, P. M., Lih, C.-J., Walsh, W., Jaffe, E. S., Rosenwald, A., Campo, E., Chan, W. C., Connors, J. M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-536433 · Cited by 626
Self-citationLocke, F. L., Neelapu, S. S., Bartlett, N. L., Siddiqi, T., Chavez, J. C., Hosing, C. M., Ghobadi, A., Budde, L. E., Bot, A., Rossi, J. M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.020 · Cited by 620
Younes, A., Sehn, L. H., Johnson, P., Zinzani, P. L., Hong, X., Zhu, J., Patti, C., Belada, D., Samoilova, O., Suh, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02403 · Cited by 608
Brudno, J. N., Somerville, R. P. T., Shi, V., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea-Banacloche, J. C., Pavletic, S. Z., Hickstein, D. D., Lu, T. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5929 · Cited by 605
Morschhauser, F., Tilly, H., Chaidos, A., McKay, P., Phillips, T., Assouline, S., Batlevi, C. L., Campbell, P., Ribrag, V., Damaj, G. L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30441-1 · Cited by 604
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 590
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3024 · Cited by 569
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214561 · Cited by 569
Sehn, L. H., & Gascoyne, R. D. (2015) · Blood · doi:10.1182/blood-2014-05-577189 · Cited by 560
Self-citationTsukasaki, K., Hermine, O., Bazarbachi, A., Ratner, L., Ramos, J. C., Harrington, W., O’Mahony, D., Janik, J. E., Bittencourt, A. L., Taylor, G. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2428 · Cited by 558
Self-citationO'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2782 · Cited by 555
Salles, G., Duell, J., González Barca, E., Tournilhac, O., Jurczak, W., Liberati, A. M., Nagy, Z., Obr, A., Gaidano, G., André, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30225-4 · Cited by 533
Self-citationZamagni, E., Patriarca, F., Nanni, C., Zannetti, B., Englaro, E., Pezzi, A., Tacchetti, P., Buttignol, S., Perrone, G., Brioli, A., et al. (2011) · Blood · doi:10.1182/blood-2011-06-361386 · Cited by 531
Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 529
Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., Hoos, A., Barrington, S. F., & Armand, P. (2016) · Blood · doi:10.1182/blood-2016-05-718528 · Cited by 521
Self-citationRubenstein, J. L., Hsi, E. D., Johnson, J. L., Jung, S.-H., Nakashima, M. O., Grant, B., Cheson, B. D., & Kaplan, L. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9957 · Cited by 509
Self-citationBollard, C. M., Gottschalk, S., Torrano, V., Diouf, O., Ku, S., Hazrat, Y., Carrum, G., Ramos, C., Fayad, L., Shpall, E. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5304 · Cited by 503
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Friedberg, J. W. (2011) · Hematology · doi:10.1182/asheducation-2011.1.498 · Cited by 497
Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002394 · Cited by 489
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 487
Self-citationHodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichenauer, D. A., Engert, A., André, M., Federico, M., Illidge, T., Hutchings, M., & Ladetto, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu181 · Cited by 474
Self-citationO'Brien, S., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., Grant, B., Richards, D. A., Coleman, M., Wierda, W. G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70513-8 · Cited by 466
Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00667-4 · Cited by 463
Self-citationBudde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00335-7 · Cited by 461
van Rhee, F., Wong, R. S., Munshi, N., Rossi, J.-F., Ke, X.-Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R. K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70319-5 · Cited by 454
Martelli, M., Ferreri, A. J. M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., & Pileri, S. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.009 · Cited by 456
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33108-2 · Cited by 453
Armand, P., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D. E., Chen, Y.-B., Kaminski, M. S., Holland, H. K., Winter, J. N., Mason, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3685 · Cited by 440
Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00010 · Cited by 434
Doubrovina, E., Oflaz-Sozmen, B., Prockop, S. E., Kernan, N. A., Abramson, S., Teruya-Feldstein, J., Hedvat, C., Chou, J. F., Heller, G., Barker, J. N., et al. (2012) · Blood · doi:10.1182/blood-2011-08-371971 · Cited by 421
Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 417
Self-citationVitolo, U., Trněný, M., Belada, D., Burke, J. M., Carella, A. M., Chua, N., Abrisqueta, P., Demeter, J., Flinn, I., Hong, X., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.3402 · Cited by 417
Mossé, Y. P., Voss, S. D., Lim, M. S., Rolland, D., Minard, C. G., Fox, E., Adamson, P., Wilner, K., Blaney, S. M., & Weigel, B. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.4830 · Cited by 413
Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635326 · Cited by 410
Self-citationRomee, R., Cooley, S., Berrien-Elliott, M. M., Westervelt, P., Verneris, M. R., Wagner, J. E., Weisdorf, D. J., Blazar, B. R., Ustun, C., DeFor, T. E., et al. (2018) · Blood · doi:10.1182/blood-2017-12-823757 · Cited by 409
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Ding, W., LaPlant, B. R., Call, T. G., Parikh, S. A., Leis, J. F., He, R., Shanafelt, T. D., Sinha, S., Le-Rademacher, J., Feldman, A. L., et al. (2017) · Blood · doi:10.1182/blood-2017-02-765685 · Cited by 407
Hermine, O., Hoster, E., Walewski, J., Bosly, A., Stilgenbauer, S., Thieblemont, C., Szymczyk, M., Bouabdallah, R., Kneba, M., Hallek, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00739-x · Cited by 400
Self-citationChen, R., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Connors, J. M., Engert, A., Larsen, E. K., Huebner, D., et al. (2016) · Blood · doi:10.1182/blood-2016-02-699850 · Cited by 395
Self-citationPhosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4648 · Cited by 395
Self-citationLin, C., Itti, E., Haioun, C., Petegnief, Y., Luciani, A., Dupuis, J., Paone, G., Talbot, J.-N., Rahmouni, A., & Meignan, M. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.042093 · Cited by 394
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412096 · Cited by 386
O’Brien, S., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., Wierda, W., Jones, J., Zhao, W., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810044 · Cited by 385
The number of people with sickle‐cell disease in the United States: national and state estimates
Brousseau, D. C., A Panepinto, J., Nimmer, M., & Hoffmann, R. G. (2010) · American Journal of Hematology · doi:10.1002/ajh.21570 · Cited by 382
18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
Weiler-Sagie, M., Bushelev, O., Epelbaum, R., Dann, E. J., Haim, N., Avivi, I., Ben-Barak, A., Ben-Arie, Y., Bar-Shalom, R., & Israel, O. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.067892 · Cited by 382
Jaccard, A., Gachard, N., Marin, B., Rogez, S., Audrain, M., Suarez, F., Tilly, H., Morschhauser, F., Thieblemont, C., Ysebaert, L., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307454 · Cited by 381
Schwartz, L. H., Seymour, L., Litière, S., Ford, R., Gwyther, S., Mandrekar, S., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.082 · Cited by 380
Viardot, A., Goebeler, M.-E., Hess, G., Neumann, S., Pfreundschuh, M., Adrian, N., Zettl, F., Libicher, M., Sayehli, C., Stieglmaier, J., et al. (2016) · Blood · doi:10.1182/blood-2015-06-651380 · Cited by 378
Ramos, C. A., Ballard, B., Zhang, H., Dakhova, O., Gee, A. P., Mei, Z., Bilgi, M., Wu, M.-F., Liu, H., Grilley, B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94306 · Cited by 375
Metadata
- Authors
- Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., Rosen, S. T., Stroobants, S., Lister, T. A., Hoppe, R. T., Dreyling, M., Tobinai, K., Vose, J. M., Connors, J. M., Federico, M., & Diehl, V.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-02-10
- Volume
- 25
- Issue
- 5
- Pages
- 579-586
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133201432
- Cited by
- 4,426
- References
- 36
- FWCI
- 108.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.